钙蛋白酶1(CAPN1)多克隆抗体

Polyclonal Antibody to Calpain 1 (CAPN1)

PIG30; CANPL1; MuCANP; MuCL; Calpain 1, Large Subunit; Calpain-1 Catalytic Subunit; Calcium-Dependent Protease 1; Calcium-activated neutral proteinase 1; Calpain mu-type; Micromolar-calpain

  • 钙蛋白酶1(CAPN1)多克隆抗体 产品包装(模拟)
  • 钙蛋白酶1(CAPN1)多克隆抗体 产品包装(模拟)
  • 钙蛋白酶1(CAPN1)多克隆抗体 DAB staining on IHC-P; Sample: Mouse Cardiac Muscle Tissue Primary Ab: 10µg/ml Rabbit Anti-Mouse CAPN1 Antibody Control: Used PBS instead of primary antibody Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
  • 钙蛋白酶1(CAPN1)多克隆抗体 DAB staining on IHC-P;
    Sample: Mouse Testis Tissue
    Primary Ab: 10µg/ml Rabbit Anti-Mouse CAPN1 Antibody
    Control: Used PBS instead of primary antibody
    Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • PAB964Mu02.jpg Figure. Western Blot; Sample: Recombinant CAPN1, Mouse.
  • 钙蛋白酶1(CAPN1)多克隆抗体 Figure. Western Blot; Sample: Lane1: Mouse Serum; Lane2: Mouse Placenta Tissue.
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对CAPN1的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别CAPN1。

用法

Western blotting: 0.5-2µg/mL;1:200-800
Immunohistochemistry: 5-20µg/mL;1:20-80
Immunocytochemistry: 5-20µg/mL;1:20-80
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

赠品

相关产品

编号 适用物种:Mus musculus (Mouse,小鼠) 应用(仅供研究使用,不用于临床诊断!)
RPB964Mu02 钙蛋白酶1(CAPN1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPB964Mu01 钙蛋白酶1(CAPN1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAB964Mu01 钙蛋白酶1(CAPN1)多克隆抗体 WB; IHC; ICC; IP.
PAB964Mu02 钙蛋白酶1(CAPN1)多克隆抗体 WB; IHC; ICC; IP.
LAB964Mu71 钙蛋白酶1(CAPN1)多克隆抗体(生物素标记) WB; IHC; ICC.
SEB964Mu 钙蛋白酶1(CAPN1)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB964Mu 钙蛋白酶1(CAPN1)等多因子检测试剂盒(流式荧光发光法) FLIA Kit for Antigen Detection.

参考文献

杂志 参考文献
Bulletin du Cancer Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma [Pubmed: 30683309]
留言咨询